Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. [Review]
- 2016
Molecularly targeted cancer therapies, such as small-molecule kinase inhibitors and monoclonal antibodies, constitute a rapidly growing and an important part of the oncology armamentarium. Unlike conventional (cytotoxic) chemotherapeutics, targeted therapies were designed to disrupt cancer cell pathogenesis at specific biological points essential for the development and progression of the tumour. These agents were developed to disrupt specific targets with the aim of minimizing treatment burden compared with conventional chemotherapy. Nevertheless the increasingly common use of targeted therapies has revealed some unanticipated, often clinically significant toxic effects, as well as compromising effective palliative and end-of-life management approaches. Although patients and clinicians welcome improvements in cancer prognosis, these changes can also impact patient quality-of-life. Therefore, as demand for oncology expertise increases, physicians need to apprise themselves of targeted therapies and their clinical implications, including drug-specific side effects, impact on quality of life, and cost issues, especially in relation to end-of-life care. This Review provides a useful summary and guide for professionals treating patients with malignant diseases.
English
1759-4774
*Antibodies, Monoclonal/tu [Therapeutic Use] *Antineoplastic Agents/tu [Therapeutic Use] *Neoplasms/dt [Drug Therapy] *Protein Kinase Inhibitors/tu [Therapeutic Use] Antibodies, Monoclonal/pd [Pharmacology] Antineoplastic Agents/pd [Pharmacology] Disease Management Drug-Related Side Effects and Adverse Reactions/cl [Classification] Drug-Related Side Effects and Adverse Reactions/di [Diagnosis] Humans Molecular Targeted Therapy/ae [Adverse Effects] Premedication Protein Kinase Inhibitors/pd [Pharmacology]